摘要
目的:探讨抗肝衰复方对重型肝炎患者临床疗效及其对细胞因子、T淋巴细胞亚群的影响。方法:将60例重型肝炎患者随机分为两组,对照组30例采用常规的西医治疗,治疗组30例在对照组基础上加用抗肝衰复方治疗,每次100ml,3次/d,14天为1个疗程,连用2～4个疗程,分别于治疗前后采用ELISA方法和流式细胞法检测白细胞介素(IL-6、IL-8、IL-10)、肿瘤坏死因子-α(TNF-α)、T淋巴细胞亚群(CD3+、CD4+、CD8+、CD4+/CD8+)的变化。统计治疗的有效率。并检测治疗前后总胆红素(TBil)、丙氨酸氨基转移酶(ALT)、白蛋白(Alb)、凝血酶原活动度(PTA)、总胆固醇(T-Chol)值。结果:治疗组显效率43.3%,总有效率70.0%;对照组显效率为20.0%,总有效率为53.3%,差异均有显著性意义(P<0.05或P<0.01)。治疗组患者治疗后TBil、PTA与对照组比较差异有显著性意义(P<0.05或P<0.01);治疗两个疗程时两组患者血清TNF-α、IL-6、IL-8水平降低具有显著的统计学意义(P<0.05);治疗后比较两组患者CD3+、CD4+、CD8+、CD4+/CD8+检测值差异有显著性意义(P<0.05)。结论:抗肝衰复方有助于改善重型肝炎患者的预后,在一定程度上调节重型肝炎患者免疫功能是其作用机制之一。
Objective： To investigate the effect of compound anti-fulminant hepatitis on cytokines and T cell subsets in patients with severe hepatitis B. Methods： Sixty patients were randomly divided into 2 groups, that was, 30 patients treated with conventional western medicine plus compound anti-fulminant hepatitis in the treated group, which was taken 100ml each time, 3 times a day and 14 days as a treating course, 30patients treated with conventional western medicine alone as a control group. The patients were treated 2 -4 treating course. TBil, ALT, Alb, PTA, T-Chol were tested. The levels of T lymphocyte subsets （CD3^＋, CD4^＋, CD8^＋, CD4^＋/CD8^＋）, interler leukine （IL-6, IL-8）, and tumor necrosis factor-α （TNF-α） were determined by using flow cytometer and ELISA before treatment and at the end 2 treating course of treatment respectively. Results： Marked improvement rate was 43.3% and total effective rate was 70. 0% in treatment group, compared to 20. 0% and 53.3% in control group. The difference was significant （P 〈0. 05）. By the end of the 2 treating course, the levels of IL-6, IL-8, TNF-α, CD3^＋ , CD4^＋ , CD8^＋ , CD4 ^＋/CD8^＋ in the treated group were significantly higher than control group （P 〈 0. 05）. Conclusion： Compound anti-fulminant hepatitis is helpful to improve prognosis of acute, subacute and chronic severe hepatitis and one of the effective measures to improve overal treatment of severe hepatitis. Compound anti-fulminant hepatitis can positively regulate the immune function of patients with severe hepatitis patients in certain.
出处
《中西医结合肝病杂志》
CAS
2007年第2期68-70,共3页
Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases
